Expression Injectable by Enhancement Medical – Adverse Events: AttorneyOne Monitors and Keeps Consumers Informed

On August 5, the US FDA issued a safety communication on adverse events associated with the unapproved use of the Expression product as a dermal filler. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Expression Injectable by Enhancement Medical: Adverse Events

Expression Injectable by Enhancement Medical: Adverse Events

We are determined to keep an eye on FDA announcements concerning Expression Injectable and inform the public.

San Diego, CA (PRWEB) August 08, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Expression Injectable.

The FDA issued a safety communication on August 5, on adverse events associated with the unapproved use of the Expression product as a dermal filler. Expression is used as an intranasal splint, intended to minimize bleeding and swelling and to prevent adhesions between the septum and the nasal cavity.

FDA’s reason for the safety communication is that the Agency became aware of adverse events, related to unapproved use, that included itching, discoloration, redness, bruising, pain, bumps, lumps, firmness, tenderness, swelling, and the development of hard nodules.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds, “We are determined to keep an eye on FDA announcements concerning Expression Injectable and inform the public. For that reason," he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

The FDA recommends that “health care providers stop using Expression by Enhancement Medical LLC as a subcutaneously administered substance and instead use the list of FDA approved fillers.” And the Agency adds “patients who have received treatment with Expression as a dermal filler should be monitored for adverse events and referred for corrective treatment when appropriate.”

AttorneyOne.com has further information on Expression Injectable at the website including latest major drug, food, and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/08/prweb12077689.htm.